Search Results - "Van Tinteren, Harm"

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial by Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., Kok, Marleen

“…The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer (TNBC) is low 1 – 5 , highlighting a need for…”
Get full text

Omission of adjuvant chemotherapy in patients with completely necrotic Wilms tumor stage I and radiotherapy in stage III: The 30‐year SIOP‐RTSG experience by Vujanić, Gordan M., Graf, Norbert, D'Hooghe, Ellen, Pritchard‐Jones, Kathy, Bergeron, Christophe, Tinteren, Harm van, Furtwängler, Rhoikos

“…Background Completely necrotic Wilms tumor (CN‐WT) following preoperative chemotherapy has been regarded as low‐risk WT since the International Society of…”
Get full text

Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges by Libes, Jaime, Hol, Janna, Neto, Joaquim Caetano de Aguirre, Vallance, Kelly L., Tinteren, Harm van, Benedetti, Daniel J., Villar, Gema Lucia Ramirez, Duncan, Catriona, Ehrlich, Peter F.

“…Pediatric renal tumors account for 3%–11% of childhood cancers, the most common of which is Wilms tumor or nephroblastoma. Epidemiology plays a key role in…”
Get full text

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921 by Brivio, Erica, Pennesi, Edoardo, Willemse, Marieke E, Huitema, Alwin D R, Jiang, Yilin, van Tinteren, Harm D R, van der Velden, Vincent H J, Beverloo, Berna H, den Boer, Monique L, Rammeloo, Lukas A J, Hudson, Chad, Heerema, Nyla, Kowalski, Karey, Zhao, Huadong, Kuttschreuter, Luke, Bautista Sirvent, Francisco J, Bukowinski, Andrew, Rizzari, Carmelo, Pollard, Jessica, Murillo-Sanjuán, Laura, Kutny, Matthew, Zarnegar-Lumley, Sara, Redell, Michele, Cooper, Stacy, Bertrand, Yves, Petit, Arnaud, Krystal, Julie, Metzler, Markus, Lancaster, Donna, Bourquin, Jean-Pierre, Motwani, Jayashree, van der Sluis, Inge M, Locatelli, Franco, Roth, Michael E, Hijiya, Nobuko, Zwaan, Christian M

“…Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 mg once daily in resistant/intolerant…”
Get full text

Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy by VERSCHUUR, Arnauld, VAN TINTEREN, Harm, GRAF, Norbert, BERGERON, Christophe, SANDSTEDT, Bengt, DE KRAKER, Jan

“…The purpose of this study was to determine the outcome of children with nephroblastoma and pulmonary metastases (PM) treated according to International Society…”
Get full text

Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer by SCHAAKE, Eva E, KAPPERS, Ingrid, CODRINGTON, Henk E, VALDES OLMOS, Renato A, TEERTSTRA, Hendrik J, PEL, Renée Van, BURGERS, Jacobus A, TINTEREN, Harm Van, KLOMP, Houke M

“…The development of targeted therapy has introduced new options to improve treatment outcome in selected patients. The objective of this prospective study was…”
Get full text

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients? by Mertens, Laura S, Meijer, Richard P, Kerst, J Martijn, Bergman, Andries M, van Tinteren, Harm, van Rhijn, Bas W G, Horenblas, Simon

“…We investigated induction carboplatin based chemotherapy in patients with nonorgan confined urothelial carcinoma who were considered unfit for cisplatin. A…”
Get more information

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma by Blank, Christian U., Rozeman, Elisa A., Fanchi, Lorenzo F., Sikorska, Karolina, van de Wiel, Bart, Kvistborg, Pia, Krijgsman, Oscar, van den Braber, Marlous, Philips, Daisy, Broeks, Annegien, van Thienen, Johannes V., Mallo, Henk A., Adriaansz, Sandra, ter Meulen, Sylvia, Pronk, Loes M., Grijpink-Ongering, Lindsay G., Bruining, Annemarie, Gittelman, Rachel M., Warren, Sarah, van Tinteren, Harm, Peeper, Daniel S., Haanen, John B. A. G., van Akkooi, Alexander C. J., Schumacher, Ton N.

“…Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients 1 , 2 . In stage IV disease, the…”
Get full text

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial by Slotman, Ben J, MD, van Tinteren, Harm, PhD, Praag, John O, MD, Knegjens, Joost L, MD, El Sharouni, Sherif Y, MD, Hatton, Matthew, FRCR, Keijser, Astrid, MSc, Faivre-Finn, Corinne, PhD, Senan, Suresh, FRCR

“…Summary Background Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have…”
Get full text

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial by Rozeman, Elisa A, Menzies, Alexander M, van Akkooi, Alexander C J, Adhikari, Chandra, Bierman, Carolien, van de Wiel, Bart A, Scolyer, Richard A, Krijgsman, Oscar, Sikorska, Karolina, Eriksson, Hanna, Broeks, Annegien, van Thienen, Johannes V, Guminski, Alexander D, Acosta, Alex Torres, ter Meulen, Sylvia, Koenen, Anne Miek, Bosch, Linda J W, Shannon, Kerwin, Pronk, Loes M, Gonzalez, Maria, Ch'ng, Sydney, Grijpink-Ongering, Lindsay G, Stretch, Jonathan, Heijmink, Stijn, van Tinteren, Harm, Haanen, John B A G, Nieweg, Omgo E, Klop, Willem M C, Zuur, Charlotte L, Saw, Robyn P M, van Houdt, Winan J, Peeper, Daniel S, Spillane, Andrew J, Hansson, Johan, Schumacher, Ton N, Long, Georgina V, Blank, Christian U

“…The outcome of patients with macroscopic stage III melanoma is poor. Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule…”
Get full text

Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol by van den Heuvel-Eibrink, Marry M, Hol, Janna A, Pritchard-Jones, Kathy, van Tinteren, Harm, Furtwängler, Rhoikos, Verschuur, Arnauld C, Vujanic, Gordan M, Leuschner, Ivo, Brok, Jesper, Rübe, Christian, Smets, Anne M, Janssens, Geert O, Godzinski, Jan, Ramírez-Villar, Gema L, de Camargo, Beatriz, Segers, Heidi, Collini, Paola, Gessler, Manfred, Bergeron, Christophe, Spreafico, Filippo, Graf, Norbert

“…The Renal Tumour Study Group of the International Society of Paediatric Oncology (SIOP-RTSG) has developed a new protocol for the diagnosis and treatment of…”
Get full text

Evidence for a delay in diagnosis of Wilms’ tumour in the UK compared with Germany: implications for primary care for children by Pritchard-Jones, Kathy, Graf, Norbert, van Tinteren, Harm, Craft, Alan

“…The UK has a longstanding system of general practice which provides the vast majority of primary care, including that for children. It acts as a 'gatekeeper'…”
Get full text

Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors by Wegert, Jenny, Ishaque, Naveed, Vardapour, Romina, Geörg, Christina, Gu, Zuguang, Bieg, Matthias, Ziegler, Barbara, Bausenwein, Sabrina, Nourkami, Nasenien, Ludwig, Nicole, Keller, Andreas, Grimm, Clemens, Kneitz, Susanne, Williams, Richard D., Chagtai, Tas, Pritchard-Jones, Kathy, van Sluis, Peter, Volckmann, Richard, Koster, Jan, Versteeg, Rogier, Acha, Tomas, O’Sullivan, Maureen J., Bode, Peter K., Niggli, Felix, Tytgat, Godelieve A., van Tinteren, Harm, van den Heuvel-Eibrink, Marry M., Meese, Eckart, Vokuhl, Christian, Leuschner, Ivo, Graf, Norbert, Eils, Roland, Pfister, Stefan M., Kool, Marcel, Gessler, Manfred

“…Blastemal histology in chemotherapy-treated pediatric Wilms tumors (nephroblastoma) is associated with adverse prognosis. To uncover the underlying tumor…”
Get full text

Optimal neoadjuvant chemotherapy duration in Wilms tumour with intravascular thrombus: A literature review and evidence from SIOP WT 2001 trial by Morris, Louise, Squire, Roly, Sznajder, Beata, Tinteren, Harm, Godzinski, Jan, Powis, Mark

“…Introduction Preoperative chemotherapy is recommended for children with Wilms tumour with intravascular extension. Extended chemotherapy may improve…”
Get full text

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study by Kersten, Marie José, Driessen, Julia, Zijlstra, Josée M, Plattel, Wouter J, Morschhauser, Franck, Lugtenburg, Pieternella J, Brice, Pauline, Hutchings, Martin, Gastinne, Thomas, Liu, Roberto, Burggraaff, Coreline N, Nijland, Marcel, Tonino, Sanne H, Arens, Anne I J, Valkema, Roelf, van Tinteren, Harm, Lopez-Yurda, Marta, Diepstra, Arjan, De Jong, Daphne, Hagenbeek, Anton

“…Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts…”
Get full text

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group by Bond, Marinde J G, Bolhuis, Karen, Loosveld, Olaf J L, de Groot, Jan Willem B, Droogendijk, Helga, Helgason, Helgi H, Hendriks, Mathijs P, Klaase, Joost M, Kazemier, Geert, Liem, Mike S L, Rijken, Arjen M, Verhoef, Cornelis, de Wilt, Johannes H W, de Jong, Koert P, Gerhards, Michael F, van Amerongen, Martinus J, Engelbrecht, Marc R W, van Lienden, Krijn P, Molenaar, I Quintus, de Valk, Bart, Haberkorn, Brigitte C M, Kerver, Emile D, Erdkamp, Frans, van Alphen, Robbert J, Mathijssen-van Stein, Daniëlle, Komurcu, Aysun, Lopez-Yurda, Marta, Swijnenburg, Rutger-Jan, Punt, Cornelis J A, Van Gulik, Thomas, Huiskens, Joost, Van Tinteren, Harm, Dejong, Cornelis H.C., Grünhagen, Dirk J., Patijn, Gijs A., Ruers, Theo J.M., Chapelle, Thiery, Hermans, John J., Leclercq, Wouter K.G., Valkenburg-van Iersel, Liselot B.J., Grootscholten, Cecile, Van Dodewaard-de Jong, Joyce M., Vincent, Jeroen, Houtsma, Danny, Los, Maartje, Den Boer, Marien, Trajkovic-Vidakovic, Marija, Van Voorthuizen, Theo, Koopman, Miriam, Vestjens, Johanneke H.M.J.V., Torrenga, Hans, Mekenkamp, Leonie J., Veldhuis, Gerrit Jan, Polee, Marco B., Dohmen, Serge E., Schut, Heidi, Vulink, Annelie J.E., Van Halteren, Henk K., Oulad Hadj, Jamal, Schiphorst, Pieter-Paul J.B.M., Hoekstra, Ronald

“…Patients with initially unresectable colorectal cancer liver metastases might qualify for local treatment with curative intent after reducing the tumour size…”
Get full text

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial by Pritchard-Jones, Kathy, Prof, Bergeron, Christophe, MD, de Camargo, Beatriz, MD, van den Heuvel-Eibrink, Marry M, MD, Acha, Tomas, MD, Godzinski, Jan, MD, Oldenburger, Foppe, MD, Boccon-Gibod, Liliane, MD, Leuschner, Ivo, Prof, Vujanic, Gordan, Prof, Sandstedt, Bengt, MD, de Kraker, Jan, MD, van Tinteren, Harm, PhD, Graf, Norbert, MD

“…Summary Background Before this study started, the standard postoperative chemotherapy regimen for stage II–III Wilms' tumour pretreated with chemotherapy was…”
Get full text

Overall survival and PD‐L1 expression in metastasized malignant melanoma by Gadiot, Jules, Hooijkaas, Anna I., Kaiser, Andrew D. M., van Tinteren, Harm, van Boven, Hester, Blank, Christian

“…BACKGROUND: Cancers are known to elude the immune system, for example, by MHC loss, FAS up‐regulation, or increased secretion of TGF‐beta. Recently, ligands of…”
Get full text

Centralization of Upper Gastrointestinal Cancer Care Should be Dictated by Quality of Care by te Riele, Wouter, van Tinteren, Harm, van Sandick, Johanna

Get full text

Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges by Libes, Jaime, Hol, Janna, Neto, Joaquim Caetano de Aguirre, Vallance, Kelly L., Tinteren, Harm van, Benedetti, Daniel J., Villar, Gema Lucia Ramirez, Duncan, Catriona, Ehrlich, Peter F.

“…Pediatric renal tumors account for 3%–11% of childhood cancers, the most common of which is Wilms tumor or nephroblastoma. Epidemiology plays a key role in…”
Get full text